Company / Cash & Equivalents
ARS Pharmaceuticals, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$41.3M
FY2025
5-year range
$41.3M / $210.5M
FY2021-FY2025
Trend
-18.7%
vs FY2024
Sector context
#188 of 207
Health Care
What the data says
Among 207 Health Care companies, ARS Pharmaceuticals, Inc. is in the bottom 9% for cash & equivalents. Cash & Equivalents has declined for 3 consecutive years, from $211M in FY2022 to $41M in FY2025.
Based on SEC 10-K filings.
$41M in FY2025 with a 5-year CAGR of -36.1%.
Declined from $71M to $41M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -41.9%
- 5-Year CAGR
- -36.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 207This company $41.3M Sector average $669.5M
▼
-93.8% below sector average
Key checks
Key Insights
- ARS Pharmaceuticals, Inc.'s cash & equivalents has declined for 3 consecutive years.
- 5-year CAGR of -36.1%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 18.7% year-over-year.
- Ranks #188 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $41.3M | -18.7% |
| FY2024 | $50.8M | -28.4% |
| FY2023 | $71.0M | -66.3% |
| FY2022 | $210.5M | +250.5% |
| FY2021 | $60.1M | -84.5% |
| FY2020 | $386.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026